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300a Monday, February 22, 2010able to increase wave frequency. On the other hand, FKBP12.6 was not (from
0.1250.04 Hz to 0.1650.04 Hz (SEM; n¼4; P>0.35). Our results indicate
that FKBP12 may have an important role as an activator of RyR2 in cardiac
cells. Further work is required to determine the individual and combined roles
of FKBP12 and FKBP12.6 in cardiac EC-coupling.
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FKBP12.6 binds tightly to RyR2 and evidence suggests that it plays a vital
physiological role in regulating channel activity. Moreover, changes in
FKBP12.6/RyR2 interactions have been implicated in heart failure. Contro-
versy exists, however, as to how FKBP12.6 affects the single-channel behav-
iour of RyR2. Furthermore, although higher levels of FKBP12 than
FKBP12.6 are present in cardiac cells, the effects of FKBP12 on RyR2 are vir-
tually unresearched. We have therefore compared the effects of FKBP12 and
FKBP12.6 on the single-channel function of sheep RyR2 incorporated into
bilayers under voltage-clamp conditions. We find that FKBP12 increases
RyR2 open probability (Po) in a dose-dependant, reversible manner with an
EC50 of 51 nM. In the presence of 10 mM cytosolic Ca
2þ, physiological levels
of FKBP12 (3 mM) increased Po from 0.18750.051 in controls to
0.65750.111 (SEM; n¼14; P<0.001). In contrast, under identical experimen-
tal conditions, FKBP12.6 did not significantly increase or decrease RyR2 Po,
however, it was able to antagonise the actions of FKBP12, shifting the EC50
value for FKBP12 to 4 mM. Our experiments demonstrate that FKBP12 has
high affinity for RyR2 and that at physiological concentrations (1-3 mM) is
an effective activator of the channel thereby suggesting that FKBP12 may
have a more important role in cardiac excitation-contraction coupling than pre-
viously thought. We hypothesise that FKBP12.6 is a very low efficacy (but high
affinity) partial agonist of RyR2 and that the balance between the effects of
FKBP12 and FKBP12.6 is crucial for normal EC-coupling in cardiac cells.
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Imperatoxin induces a biphasic response in Ca2þ sparks
Imperatoxin A (IpTxa), isolated from the venom of the African scorpion Pandi-
nus imperator, has been shown to specifically activate ryanodine receptors
(RyR) and to be capable of translocating across cell membranes. IpTxa enhances
[3H]ryanodine binding to sarcoplasmic reticulum (SR) and stabilizes subcon-
ducting states in single channels. We previously demonstrated that IpTxa alters
the amplitude of calcium transients in intact field-stimulated cells, causing
a rapid increase in transient amplitude. This is followed by a gradual decrement
in amplitude to a new steady state at lower amplitude than in control. The current
study seeks to clarify how IpTxa acts on RyRs to perturb Ca2þ handling in car-
diomyocytes. We employed visualization of IpTxa-modified Ca2þ sparks in sa-
ponin-permeabilized cells to facilitate direct titration of RyRs with known con-
centrations of IpTxa, ranging from 500pM to 50nM. In addition, we modified our
sparks protocol to enable a comparison of the caffeine-releasable SR Ca2þ load
before and after treatment with the toxin. Our results demonstrate that IpTxa in-
duces a biphasic RyR response, typified by a transient increase in spark fre-
quency, amplitude, FWHM, and FDHM, which is rapidly followed by a sharp
decrease in the same parameters. Comparison of pre- and post-toxin caffeine-re-
leasable SR Ca2þ consistently reveals that SR content has been reduced as a result
of IpTxa perfusion to approximately 75% of control. These results are consistent
with the biphasic response observed in Ca2þ transient experiments. We believe
that IpTxa sensitizes RyR to luminal Ca2þ, leading to increased Ca2þ release and
subsequent depletion of Ca2þ from the SR. Our findings have exciting implica-
tions for translational research into cardiac diseases such as catecholaminergic
polymorphic ventricular tachycardia, in which acute RyR hyperactivity is hy-
pothesized to trigger arrhythmias leading to sudden cardiac death.
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College, London, United Kingdom.Shaker B Kþ channel NH2-inactivation peptides (ShBP) block both sheep and
mouse cardiac ryanodine receptor Ca2þ release channels (RyR2). We provide
new evidence for the presence of hydrophobic residues in the conduction path-
way of RyR2 and their role in the block by wild-type (WT) and mutant ShBP.
RyR2 proteins were expressed in HEK cells, purified and their single channel
activity recorded in lipid bilayers. Four peptides were synthesised and tested: i)
WT ShBP MAAVAGLYGLGEDRQHRKKQ, ii) a ‘‘less hydrophobic’’ pep-
tide (LHBP) MAQVQGLYGLGEDRQHRKKQ, and 2 ‘‘more hydrophobic’’
peptides (MHBP), iii) MHBPI MAVVAGLYGLGEDRQHRKKQ and iv)
MHBPII MAAVVGLYGLGEDRQHRKKQ. All peptides blocked the ryano-
dine-modified RyR2 channel from the cytosolic face in a concentration- and
voltage-dependent manner. At a holding potential of þ50 mV in symmetrical
210 mM KCl, we found an affinity constant KD of 39.545 3.90 mM for WT
ShBP, 65.90 5 12.99 mM for LHBP, 27.79 5 4.29 mM for MHBPI and
44.56 5 9.38 for MHBPII. The association rates Kon of the peptides varied
with concentration (2.92 5 0.08 s1.mM1 for WT ShBP, 3.85 5 0.32
s1.mM1 for LHBP, 2.96 5 0.22 s1.mM1 for MHBPI and 2.31 5 0.25
s1.mM1 for MHBPII). Dissociation rates Koff were independent of concentra-
tion (115.305 7.90 s1 for WT ShBP, 253.525 24.49 s1 for LHBP, 82.145
5.48 s1 for MHBPI and 102.97 5 8.30 s1 for MHBPII). Furthermore the
block induced by the peptides could be reduced by an increase of the salt con-
centration at the luminal side of the channel. These findings indicate that hydro-
phobic interactions between RyR2 and inactivation peptides are necessary for
the block, and that the binding sites of the peptides are within the pore. This
research was supported by the BHF.
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Ryanodine receptors (RyRs) are large channels governing the release of Ca2þ
from the sarcoplasmic or endoplasmic reticulum. They are required for the con-
traction of both skeletal (RyR1) and cardiac muscles (RyR2). Mutations in RyR
genes have been associated with severe genetic disorders, but high-resolution
data describing the disease variants in detail has been lacking. We have solved
the crystal structures of the N-terminal domains of both RyR2 (2.55A˚) and
RyR1 (3.0A˚), along with structures of various RyR2 disease mutants. The N-
terminal domain in both RyR1 and RyR2 consists of a core beta trefoil domain
flanked by an alpha helix. Two cysteine pairs display a highly increased flexi-
bility, making them ideal candidates to receive redox modifications. Crystal
structures of several RyR2 disease mutants (1.7A˚ - 2.2A˚) show that most of
the mutations cause distinct local changes to the surface of the protein, high-
lighting at least two putative binding interfaces required for normal RyR func-
tion. One RyR2 disease mutant causes significant changes in the thermal stabil-
ity of the N-terminal domain, accompanied by large conformational changes in
the structure.
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The type 1 ryanodine receptor (RyR1) mediates excitation contraction coupling
in skeletal muscle by releasing stored intracellular calcium in response to cel-
lular depolarization. This 2.2 MDa homotetrameric protein is associated with
numerous regulatory proteins that modulate its activity in vivo. Understanding
the structure and conformational dynamics of this immense macromolecular
complex is an enormous challenge in skeletal muscle biology. In this report,
structural determinations of RyR1 were performed using Fo¨rster resonance en-
ergy transfer (FRET) measurements. In this system, the FRET donor was green
fluorescent protein (GFP) fused to RyR1, which could then transfer energy to
Cy3NTA, a site-specific FRET acceptor targeted to poly-histidine segments in-
serted into RyR1. Energy transfer was monitored as a decrease in GFP fluores-
cence occurring when Cy3NTA was bound to a His tag in close proximity to the
GFP donor fused either to position 1 or position 618 of RyR1. Cy3NTA was
targeted to each of three ‘‘divergent regions’’ (DR) poorly conserved among
the three RyR isoforms (DR1; position 4430, DR2; position 1323, DR3; posi-
tion 1861). While minimal FRET was detected between N-terminally fused
GFP and Cy3NTA targeted to these divergent regions, significant energy trans-
fer was detected from GFP at position 618 to Cy3NTA targeted to DR2 or DR3.
These experiments indicate that these donor and acceptor sites are in close
proximity to each other and also demonstrate the utility of this FRET-based
technique for further structural mapping of RyR1. (Supported by NIH grant
R21ARO56406).
